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at local level; inadequate data collection and follow-up process at later stages of 
life; poor awareness of immunisation schedule by health care practitioners (HCPs); 
lack of structural and operational policies to promote and deliver vaccination 
at later stages of life; infrequent interactions with the health care system dur-
ing adult-hood; limited and inconsistent information dissemination by HCPs and 
government; negative messages on vaccination through media; complacent public 
attitude towards the risk posed by vaccine preventable diseases. ConClusions: 
Three main domains of barriers exist: low institutional facilitation to recommend 
lifespan immunisation as part of NIP; inadequate mechanisms at regional and local 
level to facilitate citizen access to immunisation / vaccination; low patient demand 
for immunisation at older stages of life. To overcome these barriers a broad-ranging 
approach based on awareness is required, which includes providing comprehensive 
pharmacoeconomic evidence to policy makers and payers, developing information 
tracking systems that enable follow up, and HCP education to facilitate informa-
tion dissemination.
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objeCtives: The topicality of septic complications (SC) in early period after surgery 
reminds very high despite the antibiotic prophylaxis. The prediction of SC can be 
provided by ATA-test (DTE index) by the registration the structural and functional 
changes of serum albumin. Methods: Prospective observational controlled study 
of typical practice for cancer patients. Inclusion criteria: cancer patients; age – 
over 18 years; major operations. Exclusion criteria: inflammation diseases during 
3 months before surgery; extended operations on pancreas, liver and bile ducts; 
renal and/or hepatic failure. ATA-test was made ones a day during 7 days in patients 
without SC, 14 days – with SC. Data about direct medical costs was collected via 
medical charts. Analysis was performed with methods of descriptive statistic, para-
metric and non-parametric criteria. Results: Data on 104 patients were obtained: 
11 had SC. Ratio (male:female) was 1:1,4. Average age – 61.2±12.5 years. Average 
level DTE in first 2 hours after surgery in patients with SC was 15.4±7.2%, without 
SC -31.8±14%, in case SC it didn’t increase till normal meanings (40-175%) during 
7 days. Direct medical cost of patient with SC – 8838$: 5352$ - cost for medicines, 
1949$- hospitalization during 36.5 days (7.5 days in ICU), 1537$-medical services; 
without SC – 2992$: 534$-medicines, 1309$-hospitalization during 30 days (3 days in 
ICU), 1149$-medical services. ConClusions: SC can be predicted by ATA-test (DTE 
index) in first hours after surgery. It provides economy in 10 times for medicines 
and in 3 times in common direct medical costs.
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objeCtives: Information on staff resource requirements for outpatient HIV care 
is useful for effective planning of the service, especially given the increasing and 
increasingly complex patient population. The aim of this study was to estimate 
the staff resources used in the HIV outpatient clinic in Cork University Hospital 
(CUH). Methods: Staff in the CUH HIV outpatient clinic completed time sheets 
for 6 consecutive clinics (March-April 2013). Patient identifiable data were not col-
lected, however basic patient characteristics (gender, route of transmission, age > 
50 years, Irish nationality, late diagnosis) and clinical information (type of visit and 
complexity) were included. Results: Over the study period 83% (127/153) of doctor 
visits were timed. 46% of patients were seen by a senior doctor. The average length 
of time spent with each patient by senior doctors was 14.5 minutes, while NCHDs 
spent an average of 24.1 minutes per patient. Patient gender, age, route of infection, 
nationality, late diagnosis and visit type had little impact on the average length of 
doctor visit, but visit length was affected by doctor type and complexity. In addition, 
clinical nurse specialists saw 62% of patients, and spent 14.3 minutes on average 
per patient. ConClusions: Time spent with patients varies with the experience 
level of the doctor. Visit length was also affected by the individual complexity of the 
visit. The results of this study will be fed into a wider study estimating the factors 
influencing the cost of providing ambulatory HIV care in Ireland.
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objeCtives: Increasingly, human immunodeficiency virus (HIV) infection is man-
aged as a chronic condition. Payers in the United States (US) typically manage 
chronic conditions as cost-effectively as possible. One element of cost containment 
is to institute policies driving utilization of less-expensive generic medications. 
As generic HIV drugs become available, concerns arise that “de-simplifying” HIV 
treatment by incentivizing use of generic components of fixed-dose combination 
(FDC) treatments will impact adherence, resulting in adverse treatment effects. 
This study evaluated US payers’ likelihood to incentivize patients/physicians from 
branded FDCs toward a combination of generic single-dose drugs. Methods: We 
conducted targeted research of published literature and payer Web sites to identify 
information relevant to HIV coverage polices. This informed a discussion guide 
for one-on-one interviews with 10 payers from US commercial health insurance 
companies. Participants were recruited to ensure diversity from organizational 
sizes and geographical regions; interviews were double-blinded (i.e., payer and 
pharma). Results: Payers indicated HIV management is increasingly perceived as 
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objeCtives: Evidence of a significant vaccine policy shift can be witnessed not only 
in the number of new vaccines available in Japan but also in the way vaccine policy 
is being formulated. In 2010, policy makers decided for the first time ever to commis-
sion economic analyses as a reference in their consideration of subsidy allocation. 
This research offers a firsthand account of the recent changes in vaccine policies 
by examining the decision-making process from the perspective of researchers 
for economic evaluations. Methods: In order to understand the vaccine policy-
making process, we analyzed all the documents that were distributed and dis-
cussed during the government committee meetings starting from February 2010 
when the revision of the Preventive Vaccination Law was initially proposed to May 
2012 when the final recommendations were made. We then created a time-series 
table to summarize the main issues of the discussions and final conclusions from 
official reports and other relevant information recorded in the minutes. Results: 
Economic evaluations were conducted for seven vaccines under consideration for 
the routine immunization program (Hib, PCV for children and adults, HPV, vari-
cella, mumps, hepatitis B). The findings suggested most of them were cost-effective 
options. However, for the Hib vaccine, the expected savings was less than the addi-
tional costs required (23.8 billion yen increased), and for the hepatitis B vaccine, 
the incremental cost-effectiveness ratio was far beyond the acceptable range (18.3 
million yen per QALY). Nevertheless, all the vaccines were equally recommended 
for inclusion in the routine immunization program. ConClusions: The findings 
included reasons why policy makers decided to commission economic evidence 
in the first place, the importance of external influences, the choice of evaluation 
methods, the extent to which policy makers actually incorporated the economic 
evidence into new vaccine policies, and the implications of using cost-effectiveness 
analyses on the future of Japanese health policy-making.
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objeCtives: Until recently, there has not been a global focus on getting hepatitis A 
vaccines on country policy agendas. Using a vaccine policy adoption framework, we 
sought to identify drivers and barriers of hepatitis A vaccine adoption in six coun-
tries. Methods: We applied a four-part framework to identify the public vaccine 
adoption process and drivers and barriers for hepatitis A vaccine adoption: 1) evidence 
in support of hepatitis A vaccine adoption; 2) existence of supportive policies; 3) politi-
cal priority of hepatitis A within the country; and 4) whether or not the stakeholders 
were empowered and willing to act. Data were collected using a qualitative policy 
survey and a systematic literature review in Chile, India, Mexico, Russia, South Korea, 
and Taiwan between November 2011 and June 2012. Results: Because hepatitis A 
is more of a concern during periods of economic transition for most countries, and 
because it is often perceived as a non-serious illness, countries struggle to align all 
of the factors necessary for adoption. Even where solid data exist, political support 
is often waning due to apparent transition to low endemicity for hepatitis A and a 
reduced threat. Where data are lacking, other vaccines take priority. Where economic 
studies exist, narrow perspectives fail to capture the broader threat of the disease to 
regional or country economies. Hepatitis A vaccination policy is further complicated 
by the fact that as countries transition to lower endemicity, the major threat is in older 
age groups. This trend leads to a subtle shift in stakeholders from the pediatric vaccine 
community to those more focused on the adult health community. ConClusions: 
Although the vaccine adoption process is the same for hepatitis A as for other pedi-
atric vaccines, this study suggests that drivers of hepatitis A vaccine adoption may 
come from sectors outside the traditional pediatric vaccine community.
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objeCtives: Vaccination constitutes a standard element of public health preventa-
tive programmes worldwide; however, majority tend to concentrate on early stages 
of life, limiting opportunity for other population groups (adolescents, adults and 
elderly) to fully benefit. The goal of this study was to uncover barriers underpin-
ning limited and inconsistent utilisation of vaccination at all stages of life (lifespan 
immunisation). Methods: Current access to vaccination was evaluated using pub-
lically available government websites in five market archetypes based on purchase 
and delivery mechanisms. A web-based survey and subsequent in-depth interviews 
were conducted with 22 country- and European-level vaccine stakeholders to iden-
tify perceived barriers. Results: Key barriers: constrained finance and compet-
ing health care priorities; policy decisions undertaken at disease level; national 
immunisation programme (NIP) recommendations based on age and risk; poor 
influence on policy by public health practitioners and lack of vaccination advocacy 
groups; constrained finances to implement effective immunisation programmes 
